JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Strona główna・Stock List・ADMA Biologics Inc
Search

ADMA Biologics Inc

Closed

SectorHealthcare

10.5 2.74

Buy

Price update 1 maj 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

10.41

Max

10.56

Key metrics

By Trading Economics

Income

13M

49M

Sales

4.9M

139M

P/E

Sector Avg

18.217

67.147

EPS

0.216

Profit margin

35.483

Employees

640

EBITDA

14M

65M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+142.48% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2026

Market Stats

By TradingEconomics

Market Cap

-1.3B

2.5B

Previous open

7.76

Previous close

10.5

News Sentiment

By Acuity

58%

42%

299 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 23.5406 Support & Resistance

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 maj 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Read

4 maj 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Read

4 maj 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Read

4 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Read

4 maj 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

DJ

Read

4 maj 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Read

4 maj 2026, 22:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Read

4 maj 2026, 22:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Read

4 maj 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Read

4 maj 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Read

4 maj 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Read

4 maj 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Read

4 maj 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Read

4 maj 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Read

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

142.48% upside

12 Months Forecast

Average 25 USD  142.48%

High 30 USD

Low 21 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Based on 3 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 23.5406Support & Resistance

Short Term

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bullish Evidence

All events are bullish.

Long Term

Weak Bullish Evidence

There is one bullish event.

Sentiment

By Acuity

299 / 347 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Other stocks from the sector

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat